-
Innovation Ranking
NewInnovation Ranking – Fortune Brands Home & Security Inc
Fortune Brands Innovations Inc (Fortune Brands) is a manufacturer of home and security consumer products. It sells kitchen and bath cabinetry, plumbing and accessories, advanced material window products and entry door systems, and security and storage products. Fortune Brands serves kitchen and bath dealers, wholesale builders, professional remodelers, industrial and locksmith distributors, home centers, and retail outlets. The company’s major brands include Riobel, Perrin and Rowe, Shaws, Fypon, Master Lock, and Homecrest. It operates in South America, Europe, and Southeast...
-
Product Insights
Pinghu-Zhejiang Fortune Solar PV Park
Pinghu-Zhejiang Fortune Solar PV Park is a solar PV project located in Zhejiang, China. The project was developed by Zhejiang Fortune Photovoltaic Co., Ltd.. The project came online in 2014. Empower your strategies with our Pinghu-Zhejiang Fortune Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of...
-
Product Insights
Zhejiang Fortune Photovoltaic Co., Ltd. Solar PV Park
Zhejiang Fortune Photovoltaic Co., Ltd. Solar PV Park is a solar PV project located in Zhejiang, China. The project is owned and developed by Zhejiang Fortune Photovoltaic Co., Ltd.. The project came online in 2014. Empower your strategies with our Zhejiang Fortune Photovoltaic Co., Ltd. Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the...
-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Maplirpacept
Empower your strategies with our Net Present Value Model: Pfizer Inc's Maplirpacept report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Novo Nordisk AS’s Cagrisema
Empower your strategies with our Net Present Value Model: Novo Nordisk AS's Cagrisema report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Kinnate Biopharma Inc’s Exarafenib
Empower your strategies with our Net Present Value Model: Kinnate Biopharma Inc's Exarafenib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Sanofi’s Fitusiran
Empower your strategies with our Net Present Value Model: Sanofi's Fitusiran report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Saruparib
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Saruparib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s AZD-3427
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's AZD-3427 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.